Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas

Modern Pathology

Volumn 25, Issue 11, 2012, Pages 1462-1472

  Nishino, Michiya ^a   Klepeis, Veronica E ^a   Yeap, Beow Y ^a   Bergethon, Kristin ^a   Morales Oyarvide, Vicente ^a   Dias Santagata, Dora ^a   Yagi, Yukako ^a   Mark, Eugene J ^a   Iafrate, A John ^a   Mino Kenudson, Mari ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ALK; cytopathology; hepatoid cells; lung adenocarcinoma; signet ring cells; small biopsy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ADULT; AGED; ARTICLE; CELL STRUCTURE; COHORT ANALYSIS; EXCISION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, SIGNET RING CELL; FEMALE; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIVIDUALIZED MEDICINE; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 84868459016     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.109     Document Type: Article

References (31)

1. Boyle P, Levin B, (eds) World Cancer Report 2008. WHO Press: Lyon, France, 2008, pp 390-394.
2. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68:3077-3080; discussion 80.
3. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203. (Pubitemid 350235027)
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature 2007;448:561-566. (Pubitemid 47206930)
5. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23.
6. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
7. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-5590.
8. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-515.
9. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17.
10. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14:4275-4283.
11. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
12. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
13. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17: 889-897.
14. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-1733.
15. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35:1226-1234.
16. Yoshida A, Tsuta K, Watanabe S, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2010;72:309-315.
17. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALKpositive lung adenocarcinoma. J Clin Pathol 2010; 63:1066-1070.
18. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
19. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146-158.
20. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer 2010;116:659-669.
21. Solis LM, Raso MG, Kalhor N, et al. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol 2010;133:133-140.
22. Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002;26:358-364. (Pubitemid 34184460)
23. Kamiya K, Hayashi Y, Douguchi J, et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 2008;21:992-1001.
24. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003;27:101-109. (Pubitemid 36014903)
25. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.
26. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas. Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009; 63:235-240.
27. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162.
28. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-1571.
29. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011;6:466-472.
30. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in nonsmall cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011;6:459-465.
31. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012;7:348-354.